In this episode of Denatured, you'll be hearing from Edoardo Negroni, co-founder &amp; managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there. Host<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/jennifersmithparker/" target="_blank">Jennifer C. Smith-Parker</a>, Director of Insights, BioSpaceGuests<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/edoardonegroni/" target="_blank">Edoardo Negroni</a>, Co-Founder &amp; Managing Partner, AurorA-TT<a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/naveedsiddiqi/" target="_blank">Naveed Siddiqi</a>, Senior Partner, Venture Investments, Novo HoldingsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Trump’s psychedelics push, Lilly’s up to $7B CAR T deal, Replimune’s saga and Denali’s big win

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.